Abstract
1 As a class of therapeutic agents calcium antagonists have attracted increasing attention in recent years. Their major indications have been in the treatment of ischaemic myocardial syndromes, certain cardiac arrhythmias, hypertension, obstructive cardiomyopathies, and a number of lesser clinical disorders in which their role is less clearly defined. With the widening spectrum of therapeutic utility and an increasing plethora of newer agents under development, it is of importance to relate the overall pharmacodynamics of individual agents to their clinical effects.
2 Calcium antagonists have a variable specificity for cardiac and peripheral activity. Based on such activity, it is useful to construct a classification of these compounds, new and old, into four categories.
(i) Type I agents, typified by verapamil and its congeners (tiapamil and gallopamil) and diltiazem, prolong AV nodal conduction and refractoriness with little effect on ventricular or atrial refractory period. These actions account for their direct antiarrhythmic properties.
(ii) Type II agents include nifedipine and other dihydropyridines. In vivo, these agents are devoid of electrophysiologic effects in usual doses. They are potent peripheral vasodilators with some selectivity of action for different vascular beds; their overall haemodynamic effects are dominated by this peripheral vasodilatation and reflex augmentation of sympathetic reflexes.
(iii) Type III agents include flunarizine and cinnarizine (piperazine derivatives), which, in vitro and in vivo, are potent dilators of peripheral vessels, with no corresponding calcium-blocking actions in the heart.
(iv) Type IV agents are agents with a broader pharmacologic profile (perhexiline, lidoflazine and bepridil); they block calcium fluxes in the heart, in the peripheral vessels, or both. They may inhibit the fast channel in the heart and have other electrophysiologic actions.
3 A clear understanding of the varied pharmacologic properties of the different classes of calcium antagonists is likely to provide a rational basis for the use of these agents in clinical therapeutics.
Keywords: calcium antagonists, clinical application, pharmacodynamics
Full text
PDF
Images in this article
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Allen G. S., Ahn H. S., Preziosi T. J., Battye R., Boone S. C., Boone S. C., Chou S. N., Kelly D. L., Weir B. K., Crabbe R. A. Cerebral arterial spasm--a controlled trial of nimodipine in patients with subarachnoid hemorrhage. N Engl J Med. 1983 Mar 17;308(11):619–624. doi: 10.1056/NEJM198303173081103. [DOI] [PubMed] [Google Scholar]
- Brown B. G., Bolson E. L., Dodge H. T. Dynamic mechanisms in human coronary stenosis. Circulation. 1984 Dec;70(6):917–922. doi: 10.1161/01.cir.70.6.917. [DOI] [PubMed] [Google Scholar]
- DiBianco R., Alpert J., Katz R. J., Spann J., Chesler E., Ferri D. P., Larca L. J., Costello R. B., Gore J. M., Eisenman M. J. Bepridil for chronic stable angina pectoris: results of a prospective multicenter, placebo-controlled, dose-ranging study in 77 patients. Am J Cardiol. 1984 Jan 1;53(1):35–41. doi: 10.1016/0002-9149(84)90680-5. [DOI] [PubMed] [Google Scholar]
- Gelmers H. J. Nimodipine, a new calcium antagonist, in the prophylactic treatment of migraine. Headache. 1983 May;23(3):106–109. doi: 10.1111/j.1526-4610.1983.hed2303106.x. [DOI] [PubMed] [Google Scholar]
- Hecht H. S., Chew C. Y., Burnam M. H., Hopkins J., Schnugg S., Singh B. N. Verapamil in chronic stable angina: amelioration of pacing-induced abnormalities of left ventricular ejection fraction, regional wall motion, lactate metabolism and hemodynamics. Am J Cardiol. 1981 Sep;48(3):536–544. doi: 10.1016/0002-9149(81)90085-0. [DOI] [PubMed] [Google Scholar]
- Holmes B., Brogden R. N., Heel R. C., Speight T. M., Avery G. S. Flunarizine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use. Drugs. 1984 Jan;27(1):6–44. doi: 10.2165/00003495-198427010-00002. [DOI] [PubMed] [Google Scholar]
- Johnson S. M., Mauritson D. R., Willerson J. T., Hillis L. D. A controlled trial of verapamil for Prinzmetal's variant angina. N Engl J Med. 1981 Apr 9;304(15):862–866. doi: 10.1056/NEJM198104093041502. [DOI] [PubMed] [Google Scholar]
- Josephson M. A., Hecht H. S., Hopkins J., Guerrero J., Singh B. N. Comparative effects of oral verapamil and propranolol on exercise-induced myocardial ischemia and energetics in patients with coronary artery disease: single-blind placebo crossover evaluation using radionuclide ventriculography. Am Heart J. 1982 Jun;103(6):978–985. doi: 10.1016/0002-8703(82)90560-9. [DOI] [PubMed] [Google Scholar]
- Rosing D. R., Idänpän-Heikkilä U., Maron B. J., Bonow R. O., Epstein S. E. Use of calcium-channel blocking drugs in hypertrophic cardiomyopathy. Am J Cardiol. 1985 Jan 25;55(3):185B–195B. doi: 10.1016/0002-9149(85)90630-7. [DOI] [PubMed] [Google Scholar]
- Singh B. N., Baky S., Nademanee K. Second-generation calcium antagonists: search for greater selectivity and versatility. Am J Cardiol. 1985 Jan 25;55(3):214B–221B. doi: 10.1016/0002-9149(85)90634-4. [DOI] [PubMed] [Google Scholar]
- Singh B. N., Hecht H. S., Nademanee K., Chew C. Y. Electrophysiologic and hemodynamic effects of slow-channel blocking drugs. Prog Cardiovasc Dis. 1982 Sep-Oct;25(2):103–132. doi: 10.1016/0033-0620(82)90023-8. [DOI] [PubMed] [Google Scholar]
- Singh B. N., Nademanee K., Baky S. H. Calcium antagonists. Clinical use in the treatment of arrhythmias. Drugs. 1983 Feb;25(2):125–153. doi: 10.2165/00003495-198325020-00003. [DOI] [PubMed] [Google Scholar]
- Singh B. N., Nademanee K., Feld G., Piontek M., Schwab M. Comparative electrophysiologic profiles of calcium antagonists with particular reference to bepridil. Am J Cardiol. 1985 Mar 15;55(7):14C–19C. doi: 10.1016/0002-9149(85)90800-8. [DOI] [PubMed] [Google Scholar]